Canadian Cancer Statistics 2023

/0 Comments/in , /by
Now Available – Canadian Cancer Statistics 2023. This report from the Canadian Cancer Society (CCS) shows significant progress is being made to prevent lung cancer, advance early detection and improve treatments for people living with the disease. The annual report was developed by the Canadian Cancer Statistics Advisory Committee in (more…)

New Publication: Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration

/0 Comments/in , /by
The CanREValue Collaboration is excited to share our latest publication – Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration. An online version of this paper is available through Current Oncology at https://www.mdpi.com/1718-7729/30/4/286  Abstract (more…)

Article: A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada

/0 Comments/in , /by
Regier, D.A., Pollard, S., McPhail, M. et al. A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada. npj Precis. Onc. 6, 76 (2022). This important new article from CLEO is hot off the press (October 25, 2022) and was supported in part by ARCC, as well as Genome (more…)

New Publication: Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer

/0 Comments/in , /by
We are happy to announce that CanREValue’s latest publication, Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer, has been accepted for publication in JAMA Network Open. Download a copy of this paper. Abstract IMPORTANCE: To date, limited studies (more…)

New Publication: Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer

/0 Comments/in , /by
We are happy to announce that CanREValue’s latest publication, Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer, has been accepted for publication in JAMA Oncology. Download a copy of this paper. Abstract IMPORTANCE: The initial assessment of pertuzumab use for treatment of metastatic breast cancer by (more…)

New Publication: Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group

/0 Comments/in , /by
We are happy to announce that CanREValue’s latest publication, Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group, has been accepted for publication in Current Oncology. Download a copy of this paper. Abstract The Canadian (more…)

New Publication: Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces

/0 Comments/in , /by
We are excited to share this three-province cost-effectiveness analysis of bevacizumab with first line combination chemotherapy in patients with metastatic colorectal cancer. View the full text at https://journals.sagepub.com/doi/full/10.1177/23814683211021060 Download a PDF copy by Clicking Here Authors: Reka E. Pataky , Jaclyn Beca , David Tran, Wei Fang Dai, Erind Dvorani, (more…)

Updated CanREValue Interim Methods Report + Response to Stakeholder Feedback now available!

/0 Comments/in , /by
As part of a broader engagement strategy, the CanREValue Collaboration has launched a stakeholder consultation process. In 2020, the CanREValue Collaboration undertook public stakeholder consultation regarding the Interim Methods Report developed by the CanREValue Methods Working Group. From this consultation, we received 13 constructive submissions from a diverse set of (more…)

Responses to Stakeholder Feedback re: CanREValue Interim Policy Report now available!

/0 Comments/in , /by
As part of a broader engagement strategy, the CanREValue Collaboration has launched a stakeholder consultation process. Earlier in 2020, the CanREValue Collaboration undertook public stakeholder consultation regarding the Interim Policy Report developed by the CanREValue Working Groups. From this consultation, we received 21 constructive submissions from a diverse set of (more…)

Updated CanREValue Interim Data Report now available!

/0 Comments/in , /by
As part of a broader engagement strategy, the CanREValue Collaboration has launched a stakeholder consultation process. In late 2019, the CanREValue Collaboration undertook public stakeholder consultation regarding the Interim Data Report developed by the CanREValue Data Working Group. From this consultation, we received 20 constructive submissions from a diverse set (more…)